Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.58 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.47 |
| ▸ | GPR183 | P32249 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18144100 | 0.88 | CYP1A1 (0.67) | CYP1A1CYP1B1MAOBPTGS1AHR | |
| SCHEMBL18144097 | 0.88 | CYP1A1 (0.67) | CYP1A1CYP1B1MAOBPTGS1AHR | |
| SCHEMBL255255 | 0.87 | CA1 (0.58) | CYP1A1CYP1B1MAOBPTGS1AHR | |
| Hydrogen Sulfide SCHEMBL28878314 | 0.85 | CA1 (0.55) | CYP1A1CYP1B1MAOBPTGS1AHR | |
| SCHEMBL7791911 | 0.83 | CYP1A1 (0.54) | CYP1A1CYP1B1MAOBPTGS1AHR | |
| SCHEMBL7791907 | 0.83 | CYP1A1 (0.54) | CYP1A1CYP1B1MAOBPTGS1AHR | |
| SCHEMBL27883 | 0.82 | CA12 (0.65) | CYP1A1CYP1B1PTGS1AHRRAB9A | |
| SCHEMBL2096662 | 0.82 | CYP1A2 (0.52) | PTGS1AHRALDH1A1CYP1A2TSHR | |
| SCHEMBL16626095 | 0.81 | RAB9A (0.51) | CYP1A1CYP1B1MAOBPTGS1AHR | |
| SCHEMBL3992142 | 0.81 | KIF11 (0.54) | CYP1A1CYP1B1MAOBAHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423199-A1 | Substituted imidazoles and their use as pesticides | Pfizer Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| US-7825149-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-20100041712-A1 | SUBSTITUTED IMIDAZOLE COMBINATIONS | PFIZER INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-7592362-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7547718-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| US-7544706-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| EP-1981853-A1 | SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES | Pfizer Limited (GB) | 2008-10-22 | — | — | EP | disclosed |
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| WO-2007083207-A1 | SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES | PFIZER LIMITED (GB) | 2007-07-26 | — | — | WO | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | CYP1A1 30/4885CYP1B1 18/4885MAOB 186/4885 |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | CYP1A1 30/4885CYP1B1 18/4885MAOB 186/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | CYP1A1 30/4885CYP1B1 18/4885MAOB 186/4885 |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | CYP1A1 30/4885CYP1B1 18/4885MAOB 186/4885 |
| US-20100041712-A1 | SUBSTITUTED IMIDAZOLE COMBINATIONS | ING2, IGFBP2, IGFBP1 | CYP1A1 1242/4885CYP1B1 513/4885MAOB 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.